Overexpression of Bcl-X L prevents caspase-3-mediated activation of DNA fragmentation factor (DFF) produced by treatment with the photochemotherapeutic agent BPD-MA

Photodynamic therapy (PDT) is a clinically effective cancer treatment. For human promyelocytic leukemia HL-60 cells, cleavage of pro-caspase-3 (CPP32/Yama/apopain) into its proteolytically active subunits rapidly follows the photodynamic treatment of these cells with cytotoxic levels of the photosen...

Full description

Saved in:
Bibliographic Details
Published in:FEBS letters 1998-01, Vol.422 (2), p.151-154
Main Authors: Granville, David J, Jiang, Huijun, An, Mary T, Levy, Julia G, McManus, Bruce M, Hunt, David W.C
Format: Article
Language:English
Subjects:
Apoptosis
Bcl-X L
Benzoporphyrin derivative monoacid ring A
Caspase
DNA fragmentation factor
HL-60 cell
Photodynamic therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Photodynamic therapy (PDT) is a clinically effective cancer treatment. For human promyelocytic leukemia HL-60 cells, cleavage of pro-caspase-3 (CPP32/Yama/apopain) into its proteolytically active subunits rapidly follows the photodynamic treatment of these cells with cytotoxic levels of the photosensitizer benzoporphyrin derivative monoacid ring A and visible light. Cleavage of a recently identified cytosolic 45 kDa protein, DNA fragmentation factor (DFF), is required for endonuclease activation leading to DNA fragmentation. In the present study, DFF was rapidly processed following PDT. Overexpression of the anti-apoptotic Bcl-X L gene in HL-60 cells prevented PDT-induced caspase activation, DFF cleavage and DNA fragmentation. These results demonstrate for the first time an example of chemotherapeutic drug-induced activation of DFF and its regulation by Bcl-X L.
ISSN:0014-5793
1873-3468
DOI:10.1016/S0014-5793(97)01616-5